Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Pelargonium (particularly Pelargonium sidoides) has been studied for its effects on respiratory conditions, including spastic cough (a type of dry, irritating cough). The most well-documented commercial extract is known as EPs 7630. Multiple randomized, placebo-controlled clinical trials have found that Pelargonium extracts can reduce the severity and duration of cough symptoms associated with acute bronchitis and upper respiratory tract infections, which often include spastic cough. Systematic reviews and meta-analyses (e.g., Cochrane, 2013; Matthys et al., 2010) report modest but statistically significant improvements in cough frequency, severity, and recovery time compared to placebo. The proposed mechanisms include antimicrobial, antiviral, and immunomodulatory effects, as well as increased mucociliary clearance. These findings provide scientific support for its use, though most evidence is for acute bronchitis rather than specifically isolated spastic cough, and the quality of studies varies. Adverse effects are generally mild. While more high-quality research focusing on spastic cough is needed, current evidence supports the use of Pelargonium extracts as a supportive treatment for coughs with a spastic component, particularly in the context of acute respiratory infections.

More about Pelargonium (unspecified)
More about Cough (spastic)

Other ingredients used for Cough (spastic)

Other health conditions supported by Pelargonium (unspecified)

Products containing Pelargonium (unspecified)